公开(公告)号：US20240226066A1

公开(公告)日：2024-07-11

申请号：US18288592

申请日：2022-04-29

申请人： UNIVERSITE PARIS-SACLAY ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES ,  INSTITUT GUSTAVE ROUSSY

发明人： CATHERINE BRENNER ,  FRÉDÉRIC TARAN ,  JEAN-CHRISTOPHE CINTRAT ,  JEAN-LUC PERFETTINI

IPC分类号： A61K31/4174 ,  A61K31/15 ,  A61K31/513 ,  A61P9/14

CPC分类号： A61K31/4174 ,  A61K31/15 ,  A61K31/513 ,  A61P9/14

摘要： The invention relates to compounds capable of inducing autophagy and metabolic reprogramming and to the use thereof as cardioprotectors, in particular in the context of anticancer therapy.

公开(公告)号：US20230113705A1

公开(公告)日：2023-04-13

申请号：US17904910

申请日：2021-02-26

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Ceinge Biotecnologie Avanzate SCARL ,  Institut Gustave Roussy ,  Sorbonne Université ,  Université Paris Cité ,  Assistance Publique-Hôpitaux de Paris (APHP)

发明人： Chiara MAIURI ,  Guido KROEMER ,  Jonathan POL ,  Francesco SALVATORE ,  Fatima DE PALMA ,  Valentina DEL MONACO

IPC分类号： C12Q1/6886

摘要： The present invention relates to methods and compositions for the care of breast cancer, from diagnosis to treatment management. The inventors show that LINC01087 downregulation contributes to a more aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of triple-negative breast cancer. The inventors show that LINC01087 upregulation contributes to a less aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of luminal BCs. The invention relates to a method comprising the steps of: i) determining the expression level of the long intergenic non-coding RNA 01087 (LINC01087) in a sample obtained from the subject, and ii) comparing the expression level determined at step i) with a predetermined reference value, wherein detecting difference between the expression level determined at step i) and the predetermined reference value is indicative of an aggressive TNBC or less aggressive luminal BCs.

公开(公告)号：US20220168395A1

公开(公告)日：2022-06-02

申请号：US17677589

申请日：2022-02-22

申请人： Cytune Pharma ,  Institut Gustave Roussy (IGR)

发明人： David Bechard ,  Nathalie Chaput ,  Melanie Desbois

IPC分类号： A61K38/20 ,  C07K16/28 ,  C07K14/715 ,  A61K39/395 ,  C07K14/54 ,  A61K9/00 ,  A61K38/17 ,  C07K16/30

摘要： The present disclosure relates to a combined pharmaceutical composition, adapted for simultaneous, separate, or sequential administration for treating cancer in a subject comprising (a) a conjugate comprising (i) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and ii) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15Ra or derivatives thereof; a polynucleotide coding therefore, or a vector comprising such a polynucleotide; and (b) an antibody antagonizing an immune pathway implicated in the inhibition of T cell activation, or a fragment thereof, a polynucleotide coding therefore, or a vector comprising such a polynucleotide.

公开(公告)号：US11278587B2

公开(公告)日：2022-03-22

申请号：US17239056

申请日：2021-04-23

申请人： 9 METERS BIOPHARMA, INC. ,  Institut Gustave Roussy

发明人： Jay Madan ,  Sandeep Laumas

IPC分类号： A61K38/08 ,  A61K9/00 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00

摘要： The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.

公开(公告)号：US20220008514A1

公开(公告)日：2022-01-13

申请号：US17297546

申请日：2019-11-28

申请人： IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES ,  ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT GUSTAVE ROUSSY ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITE DE PARIS

发明人： Tereza COMAN ,  Francine COTE ,  Olivier HERMINE ,  Guillemette FOUQUET ,  Julien ROSSIGNOL

IPC分类号： A61K38/20 ,  A61K31/138 ,  A61K31/343 ,  A61K31/135 ,  A61K31/4525 ,  A61K31/15 ,  A61K38/18 ,  A61K38/19 ,  A61P7/06

摘要： The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.

公开(公告)号：US20210346438A1

公开(公告)日：2021-11-11

申请号：US16472778

申请日：2017-12-22

申请人： INSTITUT GUSTAVE ROUSSY ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM ,  UNIVERSITE PARIS-SUD ,  INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE - INRA

发明人： Laurence ZITVOGEL ,  Bertrand ROUTY ,  Emmanuelle LE CHATELIER

IPC分类号： A61K35/744 ,  A61K39/395 ,  C12Q1/6886 ,  C12Q1/689

摘要： The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficieny-associated dysbiosis.

公开(公告)号：US11137404B2

公开(公告)日：2021-10-05

申请号：US16061667

申请日：2016-12-16

申请人： INSTITUT GUSTAVE ROUSSY

发明人： Salem Chouaib ,  Yosra Messai ,  Muhammad Zaeem Noman

IPC分类号： G01N33/574 ,  A61K39/395

摘要： The present invention relates to a method for assessing the response of a patient to a treatment with anti-PD-1/PDL-1 drugs based on the status of the VHL gene (von Hippel-Lindau).

公开(公告)号：US20210003555A1

公开(公告)日：2021-01-07

申请号：US16630031

申请日：2018-07-13

申请人： Institut Gustave-Roussy

发明人： Charles FERTE ,  Elaine Johanna LIMKIN ,  Roger SUN ,  Eric DEUTSCH

IPC分类号： G01N33/50 ,  G06T7/00 ,  G16H30/40 ,  G16H50/20

摘要： The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor. The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and/or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1/PD-L1 monotherapy.

公开(公告)号：US20200255912A1

公开(公告)日：2020-08-13

申请号：US16843507

申请日：2020-04-08

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  INSTITUT GUSTAVE-ROUSSY ,  Assistance Publique - Hopitaux de Paris ,  Centre Henri Becquerel ,  Universite Paris Descartes ,  Universite Pierre et Marie Curie ,  Universite Paris - SUD

发明人： Franck VIGUIE ,  Olivier BERNARD ,  Michaela FONTENAY ,  Christian BASTARD ,  Francois DELHOMMEAU ,  William VAINCHENKER

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  A61K31/7068

摘要： The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

公开(公告)号：US20200239961A1

公开(公告)日：2020-07-30

申请号：US15739454

申请日：2016-06-24

申请人： Institut Gustave-Roussy

发明人： CHRISTINE BELLANNE-CHANTELOT ,  Isabelle PLO ,  William VAINCHENKER ,  Cécile SAINT-MARTIN ,  Antonio DI STEFANO ,  Joseph SALIBA

IPC分类号： C12Q1/6886 ,  G01N33/574

摘要： The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that predisposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF) secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis a secondary MDS or an AML. It also discloses a treating method for delaying MPN worsening, said treating method involving the inhibition of the ATG2B and GSKIP duplicated genes.